Thomas Eldered, CEO, at Recipharm spoke to Pharma Boardroom about the increasing expansion of the CDMO’s global footprint through acquisitions in key strategic markets. He also sheds light on why Recipharm became a public company.
Acquisitions have proven to be a key source of growth for Recipharm, allowing the company to access new markets and potential customers. Since becoming a public company in 2014 and establishing its business model as a pure CDMO, Recipharm maintains its position as a global leader in the pharmaceutical industry.
We have spent the last five years after the IPO building a global platform, getting a broad range of technologies and extending our customer base.